The launch of the company's new ovarian cancer drug Elahere is going well. Botox continues to generate billions of dollars each year. Sales of migraine drugs Ubrelvy and Qulipta are growing at ...

However, the strong sales performance of drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elahere, Epkinly and Qulipta ...

A continuation of strong growth trends is my baseline assumption for the two products. Addition of Elahere is driving the return to growth of the oncology portfolio For the oncology segment ...

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

As the target FolRα has been validated by approval and successful launch of AbbVie's (ABBV) Elahere (acquired ImmunoGen for $10 billion last year), Sutro thinks its "best in class" candidate ...